Evidence map›Paper›PMID 41455085›Full record

SynthesisLa Radiologia medica2026

Brain metastases for Her2 positive breast cancer patients: a systematic review (on the behalf of Italian Association of Radiotherapy and Clinical Oncology).

Alba Fiorentino, Roberta Carbonara, Edy Ippolito, Fiorella Cristina Di Guglielmo, Simona Borghesi, Francesca Cucciarelli, Carlotta Becherini, Samantha Dicuonzo, Ruggero Spoto, Valentina Pinzi and 3 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alba FiorentinoRadiation Oncology Department, General Regional Hospital F. Miulli, Acquaviva delle Fonti, Bari, Italy.
Roberta CarbonaraRadiation Oncology Department, General Regional Hospital F. Miulli, Acquaviva delle Fonti, Bari, Italy.
Edy IppolitoResearch Unit of Radiation Oncology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
Fiorella Cristina Di GuglielmoRadiation Oncology Department, General Regional Hospital F. Miulli, Acquaviva delle Fonti, Bari, Italy. f.diguglielmo@miulli.it.ORCID http://orcid.org/0009-0002-7553-4691
Simona BorghesiRadiation Oncology Unit of Arezzo, Valdarno Azienda USL Toscana Sud Est, Arezzo, Italy.
Francesca CucciarelliRadiotherapy Unit, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italia.
Carlotta BecheriniRadiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Samantha DicuonzoDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCSS, Milan, Italy.
Ruggero SpotoRadiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Milan, Italy.
Valentina PinziRadiotherapy Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.
Silvia ChiesaUOC Servizio di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini e Radioterapia Oncologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Silvia ScocciantiRadiation Oncology Unit, Santa Maria Annunziata Hospital Azienda USL Toscana Centro, Florence, Italy.
Isabella PalumboRadiation Oncology Unit, Perugia General Hospital and Department of Civil and Environmental Engineering, University of Perugia, Perugia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain metastases (BMs) are prevalent among patients diagnosed with human epidermal growth factor receptor 2 (HER2)positive metastatic breast cancer (BC), with the incidence rate exceeding 30%. The management of BMs typically involves multiple approaches, such as surgery, radiation therapy (RT), systemic treatments, and end-of life care. Standard brain RT includes stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (fSRT) for limited disease and whole brain radiotherapy (WBRT) for extensive disease. Recent advancements in RT and systemic treatments may change the paradigm for patients who experience prolonged survival despite BMs, especially in HER2-positive, hormone receptor (HR) positive BC patients. In recent studies, SRT for multiple BM sites (more than 4) has shown similar efficacy compared to irradiation of a limited number of lesions (1 to 3) while not increasing toxicity. This systematic review summarizes the available literature data regarding the RT approach to BMs in HER2-positive BC patients and highlights the need to optimize treatment combinations with specific emphasis on RT.

Indexed as

Brain NeoplasmsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansItalyRadiosurgeryERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBrain metastasesFractionated stereotactic radiotherapyHer2 positive metastatic breast cancer

Identifiers

PMID41455085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.